Obsidian Therapeutics (OBX) Q2 2026 earnings summary

Executive summary

• Formed April 10, 2026; activity through June 30 was limited to formation and transaction-related matters, with financial statements covering inception through June 30.

• Merger transactions closed August 3, 2026, after quarter-end; Legacy Company was renamed Obsidian Therapeutics following the mergers with Galera Therapeutics.

• Clinical-stage biopharma developing engineered tumor-infiltrating lymphocyte therapies for solid tumors using protein-regulation technology.

Significant events and developments

• SEC declared the merger registration statement effective July 2, 2026; the mergers were completed August 3, 2026.

• Disclosure controls and procedures were assessed as effective at period-end; no quarterly change in internal control over financial reporting materially affected, or was reasonably likely to materially affect, controls.

• 61,772,876 common shares outstanding as of August 10, 2026.

Capital allocation and financing

• Concurrent PIPE financing provided for $350.0 million in aggregate investor purchases of Legacy Galera Series C non-voting convertible preferred stock immediately before the merger effective time.

• Registration rights agreement provides for resale registration of certain common shares held by PIPE investors, including shares issued in the mergers in exchange for PIPE shares.